Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Nov 10 - Nov 14, 2021SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 36TH ANNUAL MEETING
Oct 7 - Oct 10, 2021AACR-NCI-EORTC VIRTUAL INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
Sep 16 - Sep 21, 2021European Society of Medical Oncology (ESMO) Virtual Congress 2021